



This is a repository copy of *Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/201419/>

Version: Published Version

---

**Article:**

Gould, R.L. [orcid.org/0000-0001-9283-1626](https://orcid.org/0000-0001-9283-1626), Rawlinson, C., Thompson, B. et al. (43 more authors) (2023) Acceptance and commitment therapy for people living with motor neuron disease: an uncontrolled feasibility study. *Pilot and Feasibility Studies*, 9. 116. ISSN 2055-5784

<https://doi.org/10.1186/s40814-023-01354-7>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.




[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

RESEARCH

Open Access



# Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study

Rebecca L. Gould<sup>1\*</sup> , Charlotte Rawlinson<sup>1</sup>, Ben Thompson<sup>2</sup>, Kirsty Weeks<sup>1</sup>, Rebecca Gossage-Worrall<sup>2</sup>, Hannah Cantrill<sup>2</sup>, Marc A. Serfaty<sup>1,3</sup>, Christopher D. Graham<sup>4</sup>, Lance M. McCracken<sup>5</sup>, David White<sup>2</sup>, Robert J. Howard<sup>1</sup>, Matt Bursnall<sup>2</sup>, Mike Bradburn<sup>2</sup>, Ammar Al-Chalabi<sup>6</sup>, Richard Orrell<sup>7</sup>, Suresh K. Chhetri<sup>8</sup>, Rupert Noad<sup>9</sup>, Aleksandar Radunovic<sup>10</sup>, Tim Williams<sup>11</sup>, Carolyn A. Young<sup>12</sup>, David Dick<sup>13</sup>, Vanessa Lawrence<sup>14</sup>, Laura H. Goldstein<sup>15</sup>, Tracey Young<sup>16</sup>, John Ealing<sup>17</sup>, Hamish McLeod<sup>18</sup>, Nicola Williams<sup>19</sup>, Helen Weatherly<sup>20</sup>, Richard Cave<sup>21</sup>, Theresa Chiwera<sup>6</sup>, Francesco Pagnini<sup>22</sup>, Cindy Cooper<sup>2</sup>, Pamela J. Shaw<sup>23</sup>, Christopher J. McDermott<sup>23</sup> and the COMMEND Collaboration Group

## Abstract

**Background** Motor neuron disease (MND) is a fatal, progressive neurodegenerative disease that causes progressive weakening and wasting of limb, bulbar, thoracic and abdominal muscles. Clear evidence-based guidance on how psychological distress should be managed in people living with MND (plwMND) is lacking. Acceptance and Commitment Therapy (ACT) is a form of psychological therapy that may be particularly suitable for this population. However, to the authors' knowledge, no study to date has evaluated ACT for plwMND. Consequently, the primary aim of this uncontrolled feasibility study was to examine the feasibility and acceptability of ACT for improving the psychological health of plwMND.

**Methods** PlwMND aged  $\geq 18$  years were recruited from 10 UK MND Care Centres/Clinics. Participants received up to 8 one-to-one ACT sessions, developed specifically for plwMND, plus usual care. Co-primary feasibility and acceptability outcomes were uptake ( $\geq 80\%$  of the target sample [ $N=28$ ] recruited) and initial engagement with the intervention ( $\geq 70\%$  completing  $\geq 2$  sessions). Secondary outcomes included measures of quality of life, anxiety, depression, disease-related functioning, health status and psychological flexibility in plwMND and quality of life and burden in caregivers. Outcomes were assessed at baseline and 6 months.

**Results** Both a priori indicators of success were met: 29 plwMND (104%) were recruited and 76% (22/29) attended  $\geq 2$  sessions. Attrition at 6-months was higher than anticipated (8/29, 28%), but only two dropouts were due to lack of acceptability of the intervention. Acceptability was further supported by good satisfaction with therapy and session attendance. Data were possibly suggestive of small improvements in anxiety and psychological quality of life from baseline to 6 months in plwMND, despite a small but expected deterioration in disease-related functioning and health status.

\*Correspondence:

Rebecca L. Gould

r.gould@ucl.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Conclusions** There was good evidence of acceptability and feasibility. Limitations included the lack of a control group and small sample size, which complicate interpretation of findings. A fully powered RCT to evaluate the clinical and cost-effectiveness of ACT for plwMND is underway.

**Trial registration** The study was pre-registered with the ISRCTN Registry (ISRCTN12655391).

**Keywords** Motor neuron disease, Acceptance and Commitment Therapy, Feasibility, Acceptability, Psychological health

### Key messages regarding feasibility

- To the authors' knowledge, No study to date has evaluated the feasibility and acceptability of Acceptance and Commitment Therapy (ACT) for people living with motor neuron disease (plwMND)
- A priori indicators of success and outcomes related to feasibility and acceptability indicated that: i) it is possible to recruit plwMND to a study of ACT for improving psychological health; and ii) ACT appears to be acceptable to this population, as demonstrated by initial engagement, session attendance and satisfaction with the intervention.
- The feasibility findings highlight that a fully powered randomised controlled trial (RCT) of ACT for improving psychological health in plwMND is justified. They further suggest that the main issues to consider in an RCT include minimising drop out, examining maintenance of effects at follow-up, and exploring ways in which results can be generalised to a broader population.

### Background

Motor neuron disease (MND) is a fatal, progressive neurodegenerative disease that predominantly affects motor neurons in the motor cortex and spinal cord, causing progressive weakening and wasting of limb, bulbar, thoracic and abdominal muscles. There is no cure for MND, and median survival is approximately 2–3 years following symptom onset, with only 4–10% surviving more than 10 years [1–3]. Furthermore, riluzole, the sole disease-modifying drug licensed in the UK, prolongs median survival for just 2–3 months at 1 year [4].

As a consequence of the nature and impact of MND symptoms and the poor prognosis, people living with MND (plwMND) and their families are faced with numerous psychological challenges, in addition to physical, social and financial difficulties. These include uncertainty due to variability in the disease course, cumulative losses in multiple domains that require continual psychological adjustment, and feelings of isolation due to a lack of awareness of MND [5, 6]. Given these challenges,

it is not surprising that some plwMND experience psychological distress during the disease course. Prevalence rates of up to 44% for depression and 30% for anxiety have been reported [7–9], with rates varying depending on assessment measures used, and higher in those with bulbar onset MND [10, 11]. Psychological distress in plwMND is associated with a range of negative outcomes, including shorter survival times, poorer quality of life and increased risks of suicide and mortality [12–16]. However, clear evidence-based guidance on how psychological distress should be managed in this population is lacking.

Current recommendations for managing psychological distress in plwMND are limited due to a lack of evidence to support such recommendations [17, 18]. Previous systematic reviews of psychological interventions to reduce psychological distress and improve psychological well-being in plwMND have highlighted limited research of varying quality [19, 20]. For example, a randomised controlled trial (RCT) of meditation training compared to usual care in 100 plwMND reported promising results with respect to quality of life, depression and anxiety, but was limited by high attrition rates (57% and 71% at 6- and 12-month follow-up, respectively) [21]. Other studies were limited by small sample sizes, lack of a control group and/or lack of follow-up assessment. Consequently, previous reviews have concluded that there is insufficient evidence to recommend specific psychological therapies for plwMND and that more research is urgently needed.

The evolution of behavioural and cognitive therapies thus far is considered to have occurred in three waves [22]: the 'first wave' of therapies (such as behavioural therapy) focus on direct behavioural change. The 'second wave' of therapies (such as traditional or conventional cognitive behavioural therapy) focus on directly changing the form or frequency of one's internal experiences (e.g. thoughts, emotions, physical sensations, etc.). In contrast, the 'third wave' of therapies (such as Acceptance and Commitment Therapy and mindfulness-based interventions) focus on changing how one relates to these internal experiences, rather than attempting to control them.

Acceptance and Commitment Therapy (ACT) may be particularly suitable for people with life-limiting illnesses

and disabling long-term conditions such as MND, muscle disorders, brain injury and chronic pain [5, 23–25]. ACT is an acceptance-based behaviour therapy [26] that has a strong evidence base in chronic pain, while the evidence base in other physical and mental health conditions is growing [27]. For example, there is preliminary evidence that ACT may be beneficial for improving psychological wellbeing in other neurodegenerative conditions, including multiple sclerosis and Parkinson's disease [28, 29].

ACT uses acceptance, mindfulness, motivational and behaviour change techniques to reduce unhelpful attempts to control, change or eliminate internal experiences (such as negative thoughts, emotions and physical sensations) and increase engagement in life-enriching activities. These techniques include helping people to be more: i) open to and accepting of their internal experiences rather than engaging in ineffective or futile struggles with them; ii) aware of their experiences and focused on the here-and-now rather than ruminating about the past or worrying about the future; and iii) committed to doing things guided by what really matters to them rather than by experiences they want to avoid.

To the authors' knowledge, no study to date has evaluated ACT in plwMND. Consequently, the primary aim of this uncontrolled study was to examine the feasibility and acceptability of ACT for improving the psychological health of plwMND. A secondary aim was to obtain preliminary estimates of 'signals of efficacy' of ACT for improving psychological health in plwMND.

## Materials and methods

All reporting is in accordance with Consolidated Standards of Reporting Trials (CONSORT) [28] and Template for Intervention Description and Replication (TIDieR) [29] guidelines. CONSORT and TIDieR checklists are provided in Additional Files 1 and 2 and additional methodological information is presented in Additional File 3. Ethical approval was granted by the London-Dulwich Research Ethics Committee (18/LO/0227).

### Design

This was a pre-registered, uncontrolled, feasibility study (ISRCTN Registry ISRCTN12655391).

### Participants

PlwMND and their caregivers were recruited from 10 UK MND Care Centres/Clinics. Eligible plwMND were aged  $\geq 18$  years with a diagnosis of definite, laboratory-supported probable or probable familial or sporadic Amyotrophic Lateral Sclerosis (ALS, which is diagnostically synonymous with MND [30]) using the World Federation of Neurology's El Escorial criteria [31].

Eligible caregivers were aged  $\geq 18$  years and were the primary caregiver of the person living with MND.

Exclusion criteria for plwMND included:

- (1) Need for gastrostomy feeding or non-invasive ventilation i.e. those in stages 4A or 4B of the King's College London clinical staging system [32], as these are markers of significantly reduced life expectancy and more advanced disease stage (and hence an indicator that participants might not survive the duration of the study);
- (2) Diagnosis of dementia using standard diagnostic guidelines [33, 34];
- (3) Currently receiving ongoing formal psychological therapy delivered by a formally trained psychologist or psychotherapist or unwilling to refrain from engaging in such formal psychological therapy during the receipt of ACT;
- (4) Insufficient understanding of English to enable engagement in ACT and completion of screening measures and patient-reported outcome measures;
- (5) Lacking capacity to provide fully informed written consent, verbal consent (for those who cannot provide written consent), or consent via the use of a communication aid;
- (6) Need for treatment for severe psychiatric disorder such as schizophrenia or bipolar disorder, or those expressing suicidal ideation with active plans/suicidal behaviours and intent;
- (7) Other medical factors that could compromise full study participation such as intellectual disabilities or severe sensory deficits.

### Procedure

Potential participants were identified and approached about the study through local clinicians, clinical and research databases, and community advertisements. Participants who provided informed consent (either written, verbally or via a communication aid) and met eligibility criteria were invited to participate. Participation in the study for plwMND involved engagement in therapy sessions and completion of outcome measures. Participation in the study for caregivers involved an invitation to attend up to three key therapy sessions (as outlined in the next section), with the consent of the person living with MND, and completion of outcome measures. All plwMND and study therapists were also invited to participate in semi-structured qualitative interviews to explore feedback in relation to delivery and receipt of the intervention. Qualitative findings will be reported elsewhere.

## Intervention

We previously made a series of recommendations as to how to adapt psychological interventions for the specific psychological, physical, communication and cognitive needs of plwMND [5]. These recommendations were based on a systematic examination of individuals' priorities and concerns [5], and a manualised ACT intervention focused on the person living with MND was developed based on these findings. The intervention comprised up to eight one-to-one sessions of ACT, supported by online audio recordings, with each session up to one hour in duration. Sessions were delivered in person within the outpatient clinic or participant's home or via video call, depending on participant preference and therapist availability. The first six sessions were weekly, and subsequent sessions were fortnightly and then monthly to facilitate sessions ending. All participants living with MND received usual multidisciplinary care in addition to ACT.

Although the intervention was focused on the person living with MND, caregivers were invited to attend the assessment session and two sessions focused on committed action, with the consent of the person living with MND. The purpose of this in the assessment session was to ensure that those involved in the care of the person living with MND were on board with the aims of ACT ('living better' rather than 'feeling better'). The purpose of this in the committed action sessions was to ensure that goals involving assistance from the caregiver were set collaboratively between the person living with MND and the caregiver. If requested by the person living with MND, the caregiver was able to attend all therapy sessions as an observer rather than active participant in therapy.

All sessions, except the first and last ones, followed the same structure. Sessions commenced with a short mindfulness exercise designed to increase awareness of the present moment. This was followed by brief ratings of how much the participant had been trying to change or get rid of difficult thoughts, feelings and sensations, how much they had been worrying about the future or dwelling on the past, and how much they had been living a life guided by what was important and really mattered to them (i.e. their values and goals). A brief assessment of suicidal ideation, including any plans, intent and protective factors, if necessary, was conducted next. Following this, there was a recap of the concepts and issues discussed in the previous session, as well as a discussion of the participant's experience of completing the home practice. The remainder of the session was spent broadly addressing a key ACT process, together with associated skills, metaphors, experiential exercises and home practice tasks, as outlined in Table 1. However, therapists were encouraged to bring other ACT processes into each session too (e.g. by asking process-specific questions),

where appropriate, so that they could respond flexibly to what was being discussed in the session (so called "dancing around the hexaflex"). See Additional File 4 for information about the core psychologically inflexible processes and their psychologically flexible counterparts, as well as examples relevant to plwMND. The pace of the sessions could be modified by the therapist, depending on the participant's needs and abilities, as therapists had a choice about which and how many metaphors and experiential exercises could be delivered in each session. The session ended with a summary of what had been discussed in the session, as well as a discussion of that week's home practice.

Therapists were qualified clinical psychologists, counselling psychologists or Cognitive Behavioural Therapists, with a minimum of one year's experience in delivering psychotherapy interventions. Therapists attended a 4-day experientially based ACT training workshop, which was developed and delivered by members of the research team with experience of ACT. This included training on: MND symptoms, prognosis and treatment; working with augmentative and alternative communication devices; psychological issues in MND; ACT core processes; ACT assessment and case conceptualisation; and adapting ACT for plwMND. ACT competency was established through an ACT Knowledge Questionnaire [35] and a clinical vignette-based quiz, developed as part of the training package. Weekly telephone group supervision was provided throughout the study delivery period by two clinical psychologists and a psychiatrist, with a minimum of five years' experience of ACT. Therapists were invited to attend on at least a fortnightly basis.

## Usual care

All participants received usual multidisciplinary care in addition to ACT comprising standard care as outlined in NICE Clinical Guideline NG42 for MND [17]. This included medication for managing MND and MND-related symptoms, treatments for MND-related symptoms (e.g. physiotherapy, non-invasive ventilation and gastrostomy), equipment and adaptations to aid activities of daily living, communication and mobility, and access to other services (including clinical psychology and neuropsychology, counselling, social care, respiratory ventilation, palliative care gastroenterology, orthotics, mobility/assistive technology/communication equipment services and community neurological care teams).

## Treatment fidelity

All therapy sessions were recorded using encrypted digital voice recorders and uploaded to a secure network server. Ten percent of sessions were randomly selected (stratified by phase of study recruitment and intervention

**Table 1** An outline of the ACT sessions, together with associated metaphors, experiential exercises and home practice

Session	Main focus of the session (with metaphors and/or experiential exercises)	Home practice
1	<p><i>Aim:</i> Assessment of current issues, goals of therapy and introduction to ACT</p> <p><i>Exercises:</i> Introducing ACT</p> <p><i>Online supplemental material:</i> Introducing ACT audio file</p>	<p>1) Notice the things that are important and matter to you and the thoughts, feelings and sensations that get in the way of this</p>
2-7 <sup>a</sup>	<p><i>ACT process:</i> Values</p> <p><i>Aim:</i> Clarify what is important and matters to you (i.e. what you want to be doing and how you want to be doing that)</p> <p><i>Exercises:</i> Centering exercise; Lifetime achievement award, Values List or Values Questions; Life compass</p> <p><i>Online supplemental material:</i> Small steps exercise audio file</p> <p><i>ACT process:</i> Acceptance</p> <p><i>Aim:</i> Explore workability of emotional control strategies and introduce an alternative to emotional control</p> <p><i>Exercises:</i> Centering exercise; Passengers on the bus; Accepting all of you or Physicalising exercise</p> <p><i>Online supplemental material:</i> Willingness exercise audio file</p> <p><i>ACT process:</i> Defusion and contact with the present moment</p> <p><i>Aim:</i> Practice skills for unhooking from thoughts, feelings and sensations in order to move towards the things that are important and matter to you</p> <p><i>Exercises:</i> Centering exercise; "I notice I'm having..."; Singing the thought or saying it in a silly voice, Writing the thought in different colours/different styles/reverse order, "Milk, milk, milk" or Imagine a thought on a computer screen; Notice 5 things or Tracking your thoughts in time</p> <p><i>Online supplemental material:</i> Leaves on a stream audio file</p> <p><i>ACT process:</i> Self-as-context</p> <p><i>Aim:</i> Practice skills for noticing the distinction between you and your thoughts, feelings and sensations in order to move towards the things that are important and matter to you</p> <p><i>Exercises:</i> Centering exercise; Labels exercise, Very brief self-as-observer and/or House/furniture metaphor</p> <p><i>Online supplemental material:</i> Connecting with the noticing you audio file</p> <p><i>ACT process:</i> Committed action</p> <p><i>Aim:</i> Explore external barriers and ways of overcoming them using selection, optimisation and compensation principles</p> <p><i>Exercises:</i> Centering exercise; Part 1 of willingness and action plan incorporating selection, optimisation and compensation principles</p> <p><i>Online supplemental material:</i> Your kind friend audio file</p> <p><i>ACT process:</i> Committed action</p> <p><i>Aim:</i> Set goals and actions in service of values</p> <p><i>Exercises:</i> Centering exercise; Part 2 of willingness and action plan incorporating selection, optimisation and compensation principles</p> <p><i>Online supplemental material:</i> Problem solving for external problems</p>	<p>1) Notice the thoughts, feelings and sensations that get in the way of the things that are important and matter to you, and what you do when they show up</p> <p>2) Take the smallest step that would move you towards one of your values</p> <p>1) Notice the thoughts, feelings and sensations that you would have to be willing to have in order to move towards the things that are important and matter to you</p> <p>2) Take the smallest step that would move you towards one of your values</p> <p>1) Practice unhooking yourself or stepping back from your thoughts, feelings and sensations in order to move towards the things that are important and that matter to you</p> <p>2) Take the smallest step that would move you towards one of your values</p> <p>1) Practice looking at your thoughts, feelings and sensations, including the stories that you tell about yourself, in a different way, from a different viewpoint in order to move towards the things that are important and matter to you</p> <p>2) Take the smallest step that would move you towards one of your values</p> <p>1) "Find another route around external barriers" in order that you can continue moving towards the things that are important and matter to you</p> <p>2) Take the smallest step that would move you towards one of your values</p> <p>1) Set and publicly commit to completing your goals and steps in service of your values</p> <p>2) Take the smallest step that would move you towards one of your values</p>
8	<p><i>Aim:</i> Review skills and concepts discussed and the metaphors and/or exercises used to illustrate them; review gains made in the sessions; and explore ways of more effectively handling thoughts, feelings and sensations in the future</p> <p><i>Exercises:</i> Centering exercise</p> <p><i>Online supplemental material:</i> Hexaflexercise audio file</p>	<p>N/A</p>

<sup>a</sup> The order of sessions 2–7 was chosen by the therapist, depending on the participant's needs and according to the individualised ACT case conceptualisation developed for each participant

and therapist) and assessed for treatment fidelity by two independent ACT therapists using the ACT Treatment Integrity Coding Manual (ACT-TICM) [36]. This comprises 14 items, rated on a scale from 1 (not at all) to 5 (extensively), which assess ACT components, anti-ACT components (i.e., such as encouraging attempts to control, change, avoid or eliminate uncomfortable thoughts and feelings), general assessment, overall adherence to the manual and overall therapist competence. Independent raters also provided feedback in relation to what therapists did well and what they could have done differently with respect to ACT. Assessment of treatment fidelity using the ACT-TICM occurred regularly throughout the study so that therapists could receive feedback on their intervention delivery.

#### Data collection

A range of socio-demographic and clinical data were collected at screening and baseline (0 months), including the Edinburgh Cognitive Behavioural ALS Screen (ECAS) [37] and the Motor Neuron Disease Behavioural Instrument (MiND-B) [38]. Outcome measures were completed at baseline and 6 months via face-to-face interview, telephone or post. This time period was chosen in order to account for variability in disease prognoses.

#### Outcomes

The co-primary outcomes and a priori indicators of success were uptake ( $\geq 80\%$  of the target sample [ $N=28$ ] recruited over the recruitment period) and initial engagement with the intervention ( $\geq 70\%$  completing at least 2 sessions), which were pre-agreed with the Funder based on their commissioning brief [39]. Secondary outcomes included additional measures of acceptability and feasibility: satisfaction with therapy at 6 months using the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R) [40]; failure to recruit and attrition due to lack of acceptability of the intervention; referral rate; and failure to recruit and attrition for reasons other than lack of acceptability of the intervention.

Secondary patient-reported outcome measures at baseline and 6 months were the McGill Quality of Life Questionnaire-Revised (MQOL-R) [41], Hospital Anxiety and Depression Scale modified for plwMND (mHADS) [42, 43], Acceptance and Action Questionnaire-II (AAQ-II) [44], EQ-5D-5L (including the Visual Analogue Scale [VAS]) [45], ALS Functional Rating Scale-Revised (ALS FRS-R) [46], Client Service Receipt Inventory (CSRI) [47] modified for plwMND, and non-physical adverse events and physical self-harm. Caregiver-reported outcome measures at baseline and 6 months were the EQ-5D-5L (plus VAS) and Zarit Burden Interview (ZBI) [48]. See Additional File 3 for further details.

#### Data analyses

Categorical measures were summarised using frequencies and percentages, while continuous measures were summarised using means and standard deviations (SDs) or medians and interquartile ranges (IQRs) for very skewed distributions. No formal data analysis was conducted, as recommended in pilot and feasibility studies [49, 50]. However, change scores across time were calculated for individuals who had observations at both baseline and 6-months, and then averaged across individuals. Cohen's  $d$  effect sizes (with accompanying confidence intervals) were also calculated by dividing the mean change score by the SD of the change scores, as previously recommended for paired data [51]. Finally, Reliable Change Index (RCI) scores [52] were calculated in order to examine whether any changes in outcome measures across time were reliable (i.e. greater in magnitude than could be explained by measurement error or artefacts of repeated measurement), based on published estimates of internal consistency [41, 44, 53–57].

#### Sample size

A sample size of 28 plwMND from 10 recruitment sites, assuming 20% attrition at 6 months [58], allowed engagement with the intervention to be estimated to within a standard error of 10%. This sample size was consistent with sample sizes of 24–35 participants conventionally recommended for pilot and feasibility studies [59–61].


## Results

#### Study flow

As shown in Fig. 1, 159 potential participants were referred to the study in July–November 2018, and 6-month follow-ups were conducted in January–May 2019. Thirty plwMND consented to participate in the study, with one participant later being found to be ineligible. Eight participants were lost to follow-up (not including the participant who was found to be ineligible), with four dropping out before receiving any therapy sessions (three due to physical health or death and one due to preferring counselling). Eighteen plwMND had a caregiver who consented to participate in the study (the rest either did not have a caregiver or did not have a caregiver who consented to participate).

#### Baseline characteristics

Baseline demographic and clinical characteristics are described in Tables 2 and 3. Of note, only a small proportion of participants reported a comorbid diagnosis of depression (5/29, 17%) or suicidal ideation (5/29, 17%), while none reported a comorbid diagnosis of anxiety. However, a third of participants (34%, 10/29) reported being prescribed psychotropic medication at baseline,



**Fig. 1** Summary of recruitment and follow-up of participants in the study

eight of which were for mood-related reasons (though only three of these reported a diagnosis of depression).

**Session delivery**

The mean number of sessions attended was 5.5 (SD 3.4; median 8.0, IQR 6.5), with 59% (17/29) attending all 8 sessions. The median waiting time for therapy was 3.3 weeks (IQR 2.6).

**Primary outcomes**

Both of the a priori targets for uptake and initial engagement with the intervention were met: 104% (29/28) of the target sample were recruited and 76% (22/29) completed at least 2 sessions.

**Secondary outcomes**

**Acceptability**

Mean scores on the STTS-R at 6 months were high (see Table 4): 79% (15/19) and 100% (19/19) of participants

rated therapy and therapists as "satisfactory" (i.e. scoring  $\geq 21/30$ ), respectively. The majority of participants (79%, 15/19) rated therapy as making things somewhat or a lot better, with none rating therapy as making things somewhat or a lot worse. Few potential participants were screened and not recruited due to not being interested in ACT (7/159, 4%), and few recruited participants were lost to follow-up due to dissatisfaction with it (2/29, 7%).

**Feasibility**

Eighteen percent (29/159) of potential participants who were screened and eligible were recruited. The majority of potential participants who were screened were not recruited for feasibility reasons, including ineligibility (48%, 62/129) and declining consent or uncontactable (14%, 18/129) (see Fig. 1). Only 14% (4/29) of recruited participants were lost to follow-up for feasibility reasons (death, physical health deterioration or hospital appointments).



**Table 2** Demographic characteristics of plwMND and caregivers

Variable	plwMND (N = 29)		Caregivers (N = 18)	
	N (missing N, %)	Mean (SD) or N (%)	N (missing N, %)	Mean (SD) or N (%)
Mean age (years)	29 (0, 0%)	58.4 (13.8), range 31–75	15 (3, 17%)	58.6 (14.9), range 29–77
Sex	29 (0, 0%)		15 (3, 17%)	
Female		14 (48%)		8 (53%)
Male		15 (52%)		7 (47%)
Marital status	29 (0, 0%)		16 (2, 11%)	
Co-habiting		2 (7%)		1 (6%)
Divorced		3 (10%)		1 (6%)
Married		20 (69%)		13 (81%)
Other		1 (3%)		0 (0%)
Single		2 (7%)		1 (6%)
Widowed		1 (3%)		0 (0%)
Ethnicity	29 (0, 0%)		15 (3, 17%)	
Asian/Asian British		0 (0%)		0 (0%)
Black/Black British		1 (3%)		0 (0%)
Mixed		0 (0%)		1 (7%)
White/White British		28 (97%)		14 (93%)
Other		0 (0%)		0 (0%)
Mean years of education	28 (1, 3%)	14.3 (3.8), range 9–21	14 (4, 22%)	13.9 (3.7), range 9–18
Employment status	29 (0, 0%)		15 (3, 17%)	
Paid work		8 (28%)		6 (40%)
Voluntary work		1 (3%)		1 (7%)
Retired		12 (41%)		5 (33%)
Not working		8 (28%)		2 (13%)
Other		0 (0%)		1 (7%)

SD Standard deviation. One participant who was recruited but later found to be ineligible is not included here

### Patient- and caregiver-reported outcomes

As no statistical analyses were conducted following previous recommendations [49, 50], changes in outcomes are presented descriptively. Data were suggestive of small improvements in anxiety and depression (mHADS) and non-physical quality of life (MQOL-R) from baseline to 6 months in plwMND (see Table 4). This was despite a small but expected deterioration in disease-related functioning (ALS FRS-R), health status (EQ-5D-5L) and physical quality of life (MQOL-R). There was no change in psychological flexibility (AAQ-II).

Table 5 presents the number of plwMND who demonstrated reliable improvement or deterioration on outcome measures at 6 months. Most notably, reliable improvement in anxiety (mHADS) and psychological quality of life (MQOL-R) was observed in three participants (17%), and was also seen for depression (mHADS) and psychological flexibility (AAQ-II) in one participant (6%). Only a small number of participants showed reliable deterioration in psychological quality of life (MQOL-R,  $N=2$ , 10%) and psychological flexibility (AAQ-II,  $N=3$ , 14%), while none showed reliable deterioration in anxiety

or depression (mHADS). In contrast, but as expected with a neurodegenerative disease, nine participants (43%) showed reliable deterioration in disease-related functioning (ALS FRS-R) and six (29%) demonstrated reliable deterioration in health status (EQ-5D-5L). However, this was not mirrored in physical quality of life (MQOL-R), most likely due to the poorer internal consistency of this sub-scale (Cronbach's  $\alpha=0.66$ ) [41]. Perhaps not surprisingly given the varied pattern of results, the number of participants demonstrating reliable improvement or deterioration in overall quality of life (MQOL-R) was mixed, with three participants (14%) demonstrating reliable improvement and four (19%) showing reliable deterioration.

As shown in Table 6, the proportion of plwMND meeting case levels on the mHADS was smaller at 6 months compared to baseline for both anxiety (baseline: 4/26, 15%; 6 months: 2/21, 10%) and depression (baseline: 3/26, 12%; 6 months: 1/21, 5%).

With respect to caregivers, data suggested a small improvement in health status on the EQ-5D-5L from baseline to 6 months (see Table 4), with one participant

**Table 3** Clinical characteristics of plwMND

Variable	N (missing N, %)	Mean (SD), median (IQR) or N (%)
Probable or definite MND	26 (3, 10%)	
Amyotrophic Lateral Sclerosis		19 (73%)
Progressive Muscular Atrophy		1 (4%)
Progressive Bulbar Palsy		1 (4%)
No MND variant specified		5 (19%)
Median months since diagnosis	27 (2, 7%)	9.0 (25.0), range 0.7–107
Median months since symptom onset	26 (3, 10%)	27.5 (38.4), range 3–166
No. prescribed riluzole	28 (1, 3%)	19 (68%)
ECAS <sup>a</sup>	29 (0, 0%)	
Mean total score (possible range 0–136)		111.9 (12.9), range 82–129
Mean ALS-specific total score (possible range 0–100)		83.4 (11.4), range 55–97
MiND-B mean total score (possible range 9–36) <sup>b</sup>	23 (6, 21%)	33.1 (3.8), range 24–36
No. with a self-reported comorbid physical health diagnosis	29 (0, 0%)	
Yes		18 (62%)
No		11 (38%)
No. with a self-reported comorbid mental health diagnosis	29 (0, 0%)	
Depression		5 (17%)
Anxiety		0 (0%)
Suicidal ideation	29 (0, 0%)	
Yes		5 (17%)
No		24 (83%)
No. prescribed psychotropic medication	29 (0, 0%)	10 (34%) <sup>c</sup>
Amitriptyline		2 (10%)
Citalopram		5 (25%)
Escitalopram		1 (5%)
Fluoxetine		1 (5%)
Sertraline		1 (5%)

One participant who was recruited but later found to be ineligible is not included here

ALS Amyotrophic lateral sclerosis, ECAS Edinburgh Cognitive Behavioural ALS Screen, IQR Interquartile range, MiND-B MND Behavioural Instrument, SD Standard deviation

<sup>a</sup> Higher scores indicate fewer cognitive symptoms

<sup>b</sup> Higher scores indicate fewer behavioural symptoms

<sup>c</sup> No participant was prescribed more than one psychotropic medication

(13%) demonstrating reliable improvement at 6 months (see Table 5). This was observed alongside a small increase in caregiver burden on the ZBI, with three participants (38%) demonstrating reliable deterioration at 6 months.

#### Adverse events

There were two reports of non-physical adverse events and two of serious adverse events. None were deemed to be related to the intervention by the Study Steering Committee.

#### Treatment fidelity

High rates of overall adherence to the manual (mean 4.9, SD 0.2) and overall ACT competence of therapists (mean

4.7, SD 0.5) were observed using the ACT-TICM. Furthermore, there was no evidence of ACT-inconsistent items in any of the rated sessions (mean 1.0, SD 0.0).

#### Discussion

This study showed that it is feasible to recruit plwMND to an uncontrolled study of ACT for improving psychological health and this type of intervention is acceptable to this population. A priori indicators of success with respect to uptake and initial engagement with therapy were met. Feasibility and acceptability of the intervention were further supported by secondary outcomes, including satisfaction with therapy and attrition rate. These indicated good evidence of acceptability and feasibility. Data were also suggestive descriptively of small

**Table 4** Mean scores, mean change scores and effect sizes at baseline and 6 months

Outcome measure	Baseline		6 months		Change score (baseline-6 months)			
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	ES	95% CI
<i>plwMND (N = 29)</i>								
Quality of life: MQOL-R								
Global (possible range 0–10)	29	6.8 (2.2)	21	7.0 (1.7)	21	0.24 (1.79)	0.13	-0.30 to 0.56
Physical (possible range 0–10)	29	5.8 (2.2)	21	5.5 (1.8)	21	0.67 (1.83)	0.36	-0.08 to 0.80
Psychological (possible range 0–10)	29	7.0 (2.6)	21	7.6 (2.1)	21	-0.12 (1.87)	-0.06	-0.49 to 0.37
Existential (possible range 0–10)	29	6.7 (2.3)	21	7.1 (1.8)	21	-0.12 (1.50)	-0.08	-0.51 to 0.35
Social (possible range 0–10)	29	8.2 (1.9)	21	8.6 (1.5)	21	-0.30 (1.50)	-0.20	-0.63 to 0.23
Total score (possible range 0–10)	29	6.9 (1.9)	21	7.2 (1.5)	21	0.03 (1.36)	0.02	-0.41 to 0.45
Mood: mHADS <sup>a</sup>								
Depression (possible range 0–18)	26	3.4 (3.2)	21	3.0 (2.6)	18	0.06 (2.44)	0.02	-0.44 to 0.48
Anxiety (possible range 0–18)	26	5.3 (4.0)	21	4.1 (3.0)	18	0.94 (2.62)	0.36	-0.12 to 0.83
Health status: EQ-5D-5L index value (possible range 0–1)	29	0.6 (0.2)	21	0.5 (0.3)	21	0.13 (0.20)	0.67	0.19 to 1.14
Health status: EQ-VAS (possible range 0–100)	29	66.3 (25.8)	21	65.0 (21.7)	21	4.86 (19.55)	0.25	-0.19 to 0.68
Disease-related functioning: ALS FRS-R (possible range 0–48)	29	35.2 (7.6)	21	30.9 (8.1)	21	4.52 (6.65)	0.68	0.20 to 1.15
Psychological flexibility: AAQ-II (possible range 7–49)	29	17.2 (8.5)	21	17.2 (7.8)	21	-0.52 (8.51)	-0.06	-0.49 to 0.37
Treatment satisfaction: STTS-R								
Satisfaction with therapy (possible range 6–30)	-	-	19	24.5 (5.0)	-	-	-	-
Satisfaction with therapist (possible range 6–30)	-	-	19	28.1 (2.3)	-	-	-	-
Global improvement (possible range 1–5)	-	-	19	2.0 (0.7)	-	-	-	-
<i>Caregivers (N = 18)</i>								
Health status: EQ-5D-5L index value (possible range 0–1)	17	0.8 (0.3)	9	0.9 (0.1)	8	-0.02 (0.07)	-0.34	-1.04 to 0.39
Health status: EQ-VAS (possible range 0–100)	17	77.4 (17.4)	9	84.0 (14.8)	8	1.75 (10.63)	0.17	-0.54 to 0.86
Caregiver burden: ZBI (possible range 0–88)	17	18.9 (14.0)	9	19.2 (15.1)	8	-8.50 (11.30)	-0.75	-1.53 to 0.06

One participant who was recruited but later found to be ineligible is not included here

AAQ-II Acceptance and Action Questionnaire-II: higher scores indicate greater psychological inflexibility, ALS FRS-R Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised: higher scores indicate better disease-related functioning, CI Confidence interval, EQ-5D-5L Higher scores indicate better health status, EQ-VAS EQ-Visual Analogue Scale: higher scores indicate better health status, ES Effect size, mHADS Hospital Anxiety and Depression Scale modified for plwMND such that one depression item and one anxiety item were not scored, as previously recommended [43]: higher scores indicate greater depression or anxiety, MQOL-R McGill Quality of Life Questionnaire-Revised: higher scores indicate better quality of life, SD standard deviation, STTS-R Satisfaction with Therapy and Therapist Scale-Revised: higher scores indicate greater satisfaction with therapy or the therapist; higher scores for global improvement indicate higher perceived improvement, ZBI Zarit Burden Interview: higher scores indicate higher caregiver burden

<sup>a</sup> One depression item and one anxiety item were not scored on the HADS, as previously recommended [43]

improvements in outcome measures from baseline to 6 months in plwMND – most notably, anxiety and psychological quality of life, which were reliably observed in 17% of participants. This was despite a small but expected deterioration in disease-related functioning and health status from baseline to 6 months, which were reliably observed in 29–43% of participants. It is important to note that, as required by the Funder (NIHR)'s commissioned call [39], plwMND were not recruited to this feasibility study on the basis of psychological distress. Furthermore, ACT is aimed at increasing life-enriching activities, alongside difficult thoughts and emotions, rather than symptomatic reduction. Therefore, small rather than large changes in psychological distress across time might be expected in this population.

As there was no control group in the current study, these small changes could simply be a product of the

disease process, a higher rate of missing outcome data at 6 months or chance observations given the small sample size. Furthermore, it is not possible to determine whether results reflect an ineffective treatment, beneficial effects being countered by deterioration due to disease progression or a possible stabilisation of these outcomes across time. In support of the latter interpretations, these results are consistent with a previous RCT of meditation training compared to usual care in plwMND [21]. This RCT reported that quality of life, depression and anxiety remained stable from baseline to 12 months in the meditation arm, but declined across time in the usual care arm. A similar pattern of stabilisation of quality of life, anxiety and depression in the treatment group compared to deterioration in the control group was recently reported in a small non-randomised controlled trial of empathy-based supportive counselling for people with

**Table 5** Reliable change in plwMND and caregivers from baseline to 6 months

Outcome measure	N	Cronbach's alpha (study ref. no.)	Reliable deterioration (N)	No reliable change (N)	Reliable improvement (N)
<i>plwMND</i>					
Quality of life: MQOL-R					
Global <sup>a</sup>	21	N/A	N/A	N/A	N/A
Physical	21	0.66 [41]	0	21	0
Psychological	21	0.85 [41]	2	16	3
Existential	21	0.78 [41]	0	21	0
Social	21	0.87 [41]	1	19	1
Total score	21	0.94 [41]	4	14	3
Mood: mHADS <sup>b</sup>					
Depression	18	0.82 [53]	0	17	1
Anxiety	18	0.83 [53]	0	15	3
Health status: EQ-5D-5L index value	21	0.83 [55]	6	15	0
Health status: EQ-VAS <sup>a</sup>	21	N/A	N/A	N/A	N/A
Disease-related functioning: ALS FRS-R	21	0.88 [54]	9	11	1
Psychological flexibility: AAQ-II	21	0.84 [44]	3	17	1
<i>Caregivers</i>					
Health status: EQ-5D-5L index value	8	0.82 [56]	0	7	1
Health status: EQ-VAS <sup>a</sup>	8	N/A	N/A	N/A	N/A
Caregiver burden: ZBI	8	0.93 [57]	3	5	0

One participant who was recruited but later found to be ineligible is not included here

AAQ-II Acceptance and Action Questionnaire-II, ALS FRS-R Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, CI Confidence interval, EQ-5D-5L EQ-VAS EQ-Visual Analogue Scale, ES Effect size, mHADS Hospital Anxiety and Depression Scale modified for plwMND such that one depression item and one anxiety item were not scored, as previously recommended [43], MQOL-R McGill Quality of Life Questionnaire-Revised, SD Standard deviation, STTS-R Satisfaction with Therapy and Therapist Scale-Revised, ZBI Zarit Burden Interview

<sup>a</sup> Measures of internal consistency do not apply to single-item measures

<sup>b</sup> One depression item and one anxiety item were not scored on the HADS, as previously recommended [43]

**Table 6** Case levels of anxiety and depression in plwMND at baseline and 6 months

Hospital Anxiety and Depression Scale modified for plwMND <sup>a</sup>	Baseline N	6 months N
Anxiety (possible range 0–18) <sup>b</sup>		
Case (score ≥ 9)	4	2
Borderline (score 7–8)	6	2
Non-case (score ≤ 6)	16	17
Missing	3	8
Depression (possible range 0–18) <sup>b</sup>		
Case (score ≥ 8)	3	1
Borderline (score 5–7)	3	2
Non-case (score ≤ 4)	20	18
Missing	3	8

One participant who was recruited but later found to be ineligible is not included here

<sup>a</sup> One anxiety item and one depression item were not scored on the HADS due to confounding with MND symptoms, as previously recommended [43]

<sup>b</sup> Recommended MND-specific scoring cut-offs for anxiety and depression are based on a Rasch analysis [43]

ALS [62]. In contrast, a small RCT of a non-meditative mindfulness intervention vs. a wait-list control for people with ALS reported stabilisation of quality of life, depression and anxiety in the control arm, but improvement in these measures in the mindfulness arm [63]. However, these findings were limited by a high attrition rate and small sample size as 47% of participants (22/47) dropped out by 6-month follow-up. These potentially conflicting results indicate that future research should seek to evaluate the clinical effectiveness of ACT adapted for plwMND in comparison to a control arm in a fully powered RCT.

We found minimal changes across time on the AAQ-II, the most common ACT process measure of psychological flexibility. Although this might indicate that the intervention resulted in little change in ACT core processes, both the construct and discriminant validity of the AAQ-II have been questioned [64–66]. In particular, it has been suggested that although the AAQ-II mainly measures psychological inflexibility, it is contaminated with distress content [64–66], and has been shown to be prone to comprehension errors in clinical

populations [67]. Consequently, future studies of ACT interventions for plwMND should consider using alternative measures of psychological flexibility such as the Comprehensive Assessment of ACT processes [68] or the Multidimensional Psychological Flexibility Inventory [69].

Twenty-eight percent (8/29) of participants were lost to follow-up in the current study, which was higher than anticipated (20% at 6-months) [58]. Reassuringly, few participants dropped out due to a lack of acceptability (2/29, 7%), with the remainder being due to feasibility issues (such as death and health deterioration). Although the attrition rate was higher than anticipated, it is important to view this in the context of rates observed in other studies of psychological interventions for plwMND. For example, an attrition rate of 57% by 6 months was reported in an RCT of meditation training, with disease progression and death being given as reasons for drop out [21]. This suggests that ways to reduce drop out due to feasibility issues need to be carefully considered in any future RCTs of psychological interventions for plwMND. Possible solutions include: i) limiting the duration of follow-up (e.g. to 9 rather than 12 months post-baseline); ii) inflating the sample size to ensure maintenance of power despite drop out; and iii) excluding those in stages 4A/4B of the King's College London clinical staging system [32], as these are markers of significantly reduced life expectancy and more advanced disease stage (and hence an indicator that participants might not survive the duration of the RCT). The fact that 39% (62/159) of potential participants were not eligible at screening in this study, mainly due to the use of non-invasive ventilation/percutaneous endoscopic gastrostomy, suggests that using the clinical staging system to reduce drop out would need to be carefully balanced with ensuring recruitment remained feasible in any future RCT.

To our knowledge, this is the first study of the acceptability, feasibility, and preliminary estimates of the effectiveness of ACT adapted for plwMND. However, there are several limitations. First, the majority of participants self-identified as White/White British and so results cannot be generalised to a broader population with MND. Second, the number of participants scoring in the clinical range for depression and anxiety at baseline (12% and 15%, respectively) and the median number of years following symptom onset (2.3 years) suggest that the sample might not be representative of all plwMND seen in MND clinics. Third, by virtue of its design, this feasibility study was not adequately powered to examine clinical effectiveness, and findings are therefore reported descriptively rather than

statistically, as recommended [49, 50]. Fourth, as participants were only followed up for 6 months, it is uncertain whether any possible stabilisation of psychological quality of life or mood was maintained beyond 6 months or whether any gains were made beyond this timepoint. Fifth, plwMND who had a need for gastrostomy feeding or non-invasive ventilation were excluded from the study in order to reduce potential attrition. Therefore, it is unclear whether ACT is beneficial for those in a more advanced disease stage. Future studies should consider ways of examining the potential effectiveness of ACT (and other psychological therapies) across the MND disease course, while at the same time minimising attrition. Finally, as noted, the lack of a control group limits the interpretation of findings. For example, the potentially smaller proportion of plwMND meeting case levels of anxiety and depression at 6-months may be due to non-specific therapeutic factors such as social support or spontaneous recovery. Therefore, descriptive results pertaining to the preliminary effectiveness of ACT for plwMND should be interpreted with caution.

## Conclusions

There was good evidence of the acceptability and feasibility of ACT for plwMND, in addition to possible signals of efficacy, particularly with respect to anxiety and psychological quality of life. However, limitations included the lack of control group and small sample size. Consequently, a fully powered RCT evaluating the clinical and cost-effectiveness of ACT adapted specifically for plwMND is currently underway [70].

## Abbreviations

AAQ-II	Acceptance and Action Questionnaire-II
ACT	Acceptance and Commitment Therapy
ACT-TICM	ACT Treatment Integrity Coding Manual
ALS	Amyotrophic Lateral Sclerosis
ALS FRS-R	ALS Functional Rating Scale-Revised
CSRI	Client Service Receipt Inventory
CONSORT	Consolidated Standards of Reporting Trials
ECAS	Edinburgh Cognitive Behavioural ALS Screen
IQR	Interquartile range
mHADS	Hospital Anxiety and Depression Scale modified for plwMND
MIND-B	Motor Neuron Disease Behavioural Instrument
MND	Motor Neuron Disease
MQOL-R	McGill Quality of Life Questionnaire-Revised
NIHR	National Institute for Health and Care Research
plwMND	People living with MND
RCI	Reliable Change Index
RCT	Randomised controlled trial
SD	Standard deviation
STTS-R	Satisfaction with Therapy and Therapist Scale-Revised
TIDieR	Template for Intervention Description and Replication
VAS	Visual Analogue Scale
ZBI	Zarit Burden Interview

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40814-023-01354-7>.

- Additional file 1.** The consolidated standards of reporting trials (CONSORT) checklist (extension for randomised pilot or feasibility trials).
- Additional file 2.** The template for intervention description and replication (TIDieR) checklist.
- Additional file 3.** Information about baseline measures and outcome measures.
- Additional file 4.** Psychologically inflexible processes and their psychologically flexible counterparts, with examples relevant to plwMND.

### Acknowledgements

We would like to thank participants who took part in the study and therapists who delivered the intervention. We would also like to thank members of our Patient Caregiver Advisory Group who attended meetings, provided advice and guidance about key issues, contributed to the development and revision of the intervention manual, and provided feedback on study materials. Finally, we would like to thank members of the Trial Steering Committee and Data Monitoring and Ethics Committee (Professors Carl Clarke, Karen Morrison and Hugh Rickards, and Drs Heather Murray and Robin Young) for their advice and guidance throughout the study.

RG, MS and RH are supported by the NIHR University College London Hospitals Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London. MBr, TY, CC, PS and CM are supported by the NIHR Sheffield Biomedical Research Centre. AA-C, VL and LG are supported by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. AA-C is an NIHR Senior Investigator (NIHR202421). This project is supported through the following funding organisations under the aegis of JPND – [www.jpnd.eu](http://www.jpnd.eu) (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1) and through the Motor Neurone Disease Association, My Name's Doddie Foundation, and Alan Davidson Foundation.

Individual members of the COMMEND Collaboration Group are (in alphabetical order): Annmarie Burns, Caroline Dancyger, Annily Dee, Susie Henley, Mark Howell, Naoko Kishita, Selina Makin, Emily Mayberry, Mark Oliver, Alexandra Richards, Emma Robinson and Liz Tallentire.

### Authors' contributions

RG, DW, MS, CG, LM, MBr, TY, RH, AA-C, LG, VL, CC, PS and CM conceptualised the idea and obtained funding for the trial. RG, MS, CG, LM, RH, VL, LG, RC, FP and CM were involved in the development and/or delivery of the intervention manual and training. RG, MS, CG and LM supervised therapists in the delivery of the intervention. BT, RG-W, HC, RG and DW oversaw the day-to-day running of the study. MS, CG, LM, DW, RH, MBu, MBr, AA-C, VL, LG, TY, JE, HM, NW, HW, CC, PS and CM provided advice on study management. CR, KW, AA-C, RO, SC, RN, AR, TW, CY, DD, TC and CM were involved in participant recruitment and/or data collection. RG, BT, MBu and MBr were involved in data analysis. RG drafted the manuscript, and all authors read and approved the final manuscript.

### Funding

This work was supported by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Programme (grant number 16/81/01) and the Motor Neurone Disease Association (grant number Gould/Jul17/936–794). The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. The NIHR commissioned the research and had an initial role in stipulating brief details about the study design. The NIHR and the Motor Neurone Disease Association have not been involved in study design, collection/analysis/interpretation of data or manuscript preparation.

### Availability of data and materials

The dataset used and/or analysed during the current study is available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

Ethical approval was granted by the London-Dulwich Research Ethics Committee (18/LO/0227). All eligible participants were invited to provide fully informed written consent, verbal consent (for those who could not provide written consent due to mobility issues), or consent via the use of a communication aid to participate in the trial, in line with Sheffield Clinical Trial Research Unit's standard operating procedures and as approved by the London-Dulwich Research Ethics Committee. An independent witness was asked to sign the consent form to verify the consent taken in all cases where non-written consent was obtained.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Division of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London W1T 7NF, UK. <sup>2</sup>Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK. <sup>3</sup>Priory Hospital North London, London, UK. <sup>4</sup>Strathclyde Psychology, Department of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK. <sup>5</sup>Department of Psychology, Uppsala University, Uppsala, Sweden. <sup>6</sup>Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK. <sup>7</sup>Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK. <sup>8</sup>Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK. <sup>9</sup>Department of Neuropsychology, Derriford Hospital, Plymouth, UK. <sup>10</sup>Barts Health NHS Trust, London, UK. <sup>11</sup>The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. <sup>12</sup>The Walton Centre NHS Foundation Trust, Liverpool, UK. <sup>13</sup>Norfolk and Norwich University Hospital, Norwich, UK. <sup>14</sup>Health Services & Population Research Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. <sup>15</sup>Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. <sup>16</sup>School of Health and Related Research, University of Sheffield, Sheffield, UK. <sup>17</sup>Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. <sup>18</sup>Mental Health and Wellbeing, University of Glasgow, Glasgow, UK. <sup>19</sup>Primary Care Clinical Trials Unit, Oxford University, Oxford, UK. <sup>20</sup>Centre for Health Economics, University of York, York, UK. <sup>21</sup>Language and Cognition, University College London, London, UK. <sup>22</sup>Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy. <sup>23</sup>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.

Received: 13 March 2023 Accepted: 27 June 2023

Published online: 07 July 2023

### References

- Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. *Nat Rev Neurol*. 2013;9(11):617–28.
- Chiò A, Logroscino G, Hardiman O, Swinger R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. *Amyotroph Lateral Scler*. 2009;10(5–6):310–23.
- Turner MR. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990–2002. *J Neurol Neurosurg Psychiatry*. 2003;74(7):995–7.
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Neuromuscular Group, editor. Cochrane Database Syst Rev*. 2012 [cited 2022 Apr 5]; Available from: <https://doi.wiley.com/10.1002/14651858.CD001447.pub3>.
- Weeks KR, Gould RL, Mcdermott C, Lynch J, Goldstein LH, Graham CD, et al. Needs and preferences for psychological interventions of people with motor neuron disease. *Amyotroph Lateral Scler Front Degener*. 2019;20(7–8):521–31.
- Pinto C, Geraghty AWA, Yardley L, Dennison L. Emotional distress and well-being among people with motor neurone disease (MND)

- and their family caregivers: a qualitative interview study. *BMJ Open*. 2021;11(8):e044724.
7. Averill AJ, Kasarskis EJ, Segerstrom SC. Psychological health in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler*. 2007;8(4):243–54.
  8. Kurt A, Nijboer F, Matuz T, Kubler A. Depression and Anxiety in Individuals with Amyotrophic Lateral Sclerosis: Epidemiology and Management. *CNS Drugs*. 2007;21(4):279–91.
  9. Taylor L, Wicks P, Leigh PN, Goldstein LH. Prevalence of depression in amyotrophic lateral sclerosis and other motor disorders. *Eur J Neurol*. 2010;17(8):1047–53.
  10. Goldstein LH, Atkins L, Landau S, Brown RG, Leigh PN. Longitudinal predictors of psychological distress and self-esteem in people with ALS. *Neurology*. 2006;67(9):1652–8.
  11. Hogg KE, Goldstein LH, Leigh PN. The psychological impact of motor neurone disease. *Psychol Med*. 1994;24(3):625–32.
  12. Fang F, Valdimarsdóttir U, Fürst CJ, Hultman C, Fall K, Sparén P, et al. Suicide among patients with amyotrophic lateral sclerosis. *Brain*. 2008;131(10):2729–33.
  13. McDonald ER. Survival in Amyotrophic Lateral Sclerosis: The Role of Psychological Factors. *Arch Neurol*. 1994;51(1):17.
  14. Johnston M, Earll L, Giles M, McClenahan R, Stevens D, Morrison V. Mood as a predictor of disability and survival in patients newly diagnosed with ALS/MND. *Br J Health Psychol*. 1999;4(2):127–36.
  15. Pizzimenti A. Depression, pain and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study. *Funct Neurol*. 2013;28(2):115–9.
  16. van Groenestijn AC, Kruitwagen-van Reenen ET, Visser-Meily JMA, van den Berg LH, Schröder CD. Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review. *Health Qual Life Outcomes*. 2016;14(1):107.
  17. National Institute for Health and Care Excellence. Motor neurone disease: Assessment and management (NG42). 2016. Available from: [www.nice.org.uk/Guidance/NG42](http://www.nice.org.uk/Guidance/NG42).
  18. Simpson J, Eccles F, Zarotti N. Psychological interventions for people with Huntington's disease, Parkinson's disease, motor neurone disease, and multiple sclerosis: Evidence-based guidance [Internet]. British Psychological Society; 2021. Available from: <https://www.bps.org.uk/sites/www.bps.org.uk/files/Policy/Policy%20-%20Files/Psychological%20interventions%20-%20Huntingtons%20-%20Parkinsons%20-%20motor%20neurone%20disease%20-%20multiple%20sclerosis.pdf>.
  19. Gould RL, Coulson MC, Brown RG, Goldstein LH, Al-Chalabi A, Howard RJ. Psychotherapy and pharmacotherapy interventions to reduce distress or improve well-being in people with amyotrophic lateral sclerosis: A systematic review. *Amyotroph Lateral Scler Front Degener*. 2015;16(5–6):293–302.
  20. Zarotti N, Mayberry E, Ovaska-Stafford N, Eccles F, Simpson J. Psychological interventions for people with motor neuron disease: a scoping review. *Amyotroph Lateral Scler Front Degener*. 2021;22(1–2):1–11.
  21. Pagnini F, Marconi A, Tagliaferri A, Manzoni GM, Gatto R, Fabiani V, et al. Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial. *Eur J Neurol*. 2017;24(4):578–86.
  22. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. *Behav Ther*. 2004;35(4):639–65.
  23. Rose MR, Graham CD, O'Connell N, Vari C, Edwards V, Taylor E, et al. A randomised controlled trial of acceptance and commitment therapy for improving quality of life in people with muscle diseases. *Psychol Med*. 2023;53(8):3511–24.
  24. Kangas M, McDonald S. Is it time to act? The potential of acceptance and commitment therapy for psychological problems following acquired brain injury. *Neuropsychol Rehabil*. 2011;21(2):250–76.
  25. McCracken LM, Yu L, Vowles KE. New generation psychological treatments in chronic pain. *BMJ*. 2022;28:e057212.
  26. Hayes S, Strosahl K, Wilson K. *Acceptance and Commitment Therapy: The process and practice of mindful change*. 2nd ed. New York: Guilford Press; 2012.
  27. Gloster AT, Walder N, Levin ME, Twohig MP, Karekla M. The empirical status of acceptance and commitment therapy: A review of meta-analyses. *J Context Behav Sci*. 2020;18:181–92.
  28. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;24(355):i5239.
  29. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;7(348):g1687.
  30. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. *Lancet Neurol*. 2016;15(11):1182–94.
  31. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2000;1(5):293–9.
  32. Roche JC, Rojas-García R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. *Brain*. 2012;135(3):847–52.
  33. Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Front Degener*. 2017;18(3–4):153–74.
  34. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263–9.
  35. Luoma JB, Vilardaga JP. Improving Therapist Psychological Flexibility While Training Acceptance and Commitment Therapy: A Pilot Study. *Cogn Behav Ther*. 2013;42(1):1–8.
  36. Plumb JC, Vilardaga R. Assessing treatment integrity in acceptance and commitment therapy: Strategies and suggestions. *Int J Behav Consult Ther*. 2010;6(3):263–95.
  37. Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders. *Amyotroph Lateral Scler Front Degener*. 2015;16(3–4):172–9.
  38. Mioshi E, Hsieh S, Caga J, Ramsey E, Chen K, Lillo P, et al. A novel tool to detect behavioural symptoms in ALS. *Amyotroph Lateral Scler Front Degener*. 2014;15(3–4):298–304.
  39. National Institute for Health Research Health Technology Assessment Programme. Intervention to improve the psychological health of people with motor neurone disease. [Internet]. 2016. Available from: <https://fundingawards.nihr.ac.uk/award/16/81/01>.
  40. Oei TPS, Green AL. The Satisfaction With Therapy and Therapist Scale-Revised (STTS-R) for group psychotherapy: Psychometric properties and confirmatory factor analysis. *Prof Psychol Res Pract*. 2008;39(4):435–42.
  41. Cohen SR, Sawatzky R, Russell LB, Shahidi J, Heyland DK, Gadermann AM. Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire-Revised. *Palliat Med*. 2017;31(2):120–9.
  42. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67(6):361–70.
  43. Gibbons CJ, Mills RJ, Thornton EW, Ealing J, Mitchell JD, Shaw PJ, et al. Rasch analysis of the hospital anxiety and depression scale (hads) for use in motor neurone disease. *Health Qual Life Outcomes*. 2011;9(1):82.
  44. Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, et al. Preliminary Psychometric Properties of the Acceptance and Action Questionnaire-II: A Revised Measure of Psychological Inflexibility and Experiential Avoidance. *Behav Ther*. 2011;42(4):676–88.
  45. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727–36.
  46. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. *J Neurol Sci*. 1999;169(1–2):13–21.
  47. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, Brewin C, Wing J, editors. *Measuring Mental Health Needs*. London, UK: Gaskell/Royal College of Psychiatrists; 1992. p. 163–83.
  48. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the Impaired Elderly: Correlates of Feelings of Burden. *Gerontologist*. 1980;20(6):649–55.
  49. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: Recommendations for good practice: Design and analysis of pilot studies. *J Eval Clin Pract*. 2004;10(2):307–12.
  50. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. *BMC Med Res Methodol*. 2010;10(1):1.
  51. Dankel SJ, Loenneke JP. Effect Sizes for Paired Data Should Use the Change Score Variability Rather Than the Pre-test Variability. *J Strength Cond Res*. 2018 [cited 2023 Jan 29]; Publish Ahead of Print. Available from: <https://journals.lww.com/00124278-900000000-95075>.

52. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. *J Consult Clin Psychol*. 1991;59(1):12–9.
53. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. *J Psychosom Res*. 2002;52(2):69–77.
54. Franchignoni F, Mora G, Giordano A, Volanti P, Chiò A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. *J Neurol Neurosurg Psychiatry*. 2013;84(12):1340–5.
55. Alvarado-Bolaños A, Cervantes-Arriaga A, Rodríguez-Violante M, Llorens-Arenas R, Calderón-Fajardo H, Millán-Cepeda R, et al. Convergent validation of EQ-5D-5L in patients with Parkinson's disease. *J Neurol Sci*. 2015;358(1–2):53–7.
56. Xu RH, Keetharath AD, Wang LL, Cheung AWL, Wong ELY. Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A. *Eur J Health Econ*. 2022;23(2):165–76.
57. Seng BK, Luo N, Ng WY, Lim J, Chionh HL, Goh J, et al. Validity and reliability of the Zarit Burden Interview in assessing caregiving burden. *Ann Acad Med Singapore*. 2010;39(10):758–63.
58. Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, et al. A phase II–III trial of olesoxime in subjects with amyotrophic lateral sclerosis. *Eur J Neurol*. 2014;21(3):529–36.
59. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. *Trials*. 2014;15(1):264.
60. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat*. 2005;4(4):287–91.
61. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat Methods Med Res*. 2016;25(3):1057–73.
62. Palmieri A, Kleinbub JR, Pagnini F, Sorarù G, Cipolletta S. Empathy-based supportive treatment in amyotrophic lateral sclerosis: A pragmatic study. *Am J Clin Hypn*. 2021;63(3):202–16.
63. Pagnini F, Phillips D, Haulman A, Bankert M, Simmons Z, Langer E. An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial. *Amyotroph Lateral Scler Front Degener*. 2022;23(1–2):116–27.
64. Wolgast M. What Does the Acceptance and Action Questionnaire (AAQ-II) Really Measure? *Behav Ther*. 2014;45(6):831–9.
65. Tyndall I, Waldeck D, Pancani L, Whelan R, Roche B, Dawson DL. The Acceptance and Action Questionnaire-II (AAQ-II) as a measure of experiential avoidance: Concerns over discriminant validity. *J Context Behav Sci*. 2019;12:278–84.
66. Rogge RD, Daks JS, Dubler BA, Saint KJ. It's all about the process: Examining the convergent validity, conceptual coverage, unique predictive validity, and clinical utility of ACT process measures. *J Context Behav Sci*. 2019;14:90–102.
67. Castle HV. Using Cognitive Interviewing to assess the Validity of Acceptance and Commitment Therapy (ACT) Questionnaires in individuals with Chronic Pain [D.Clin.Psychol thesis]. University of Leeds; 2019. Available from: [https://etheses.whiterose.ac.uk/25119/1/Castle\\_HV\\_DClinPsychol\\_2019.pdf](https://etheses.whiterose.ac.uk/25119/1/Castle_HV_DClinPsychol_2019.pdf).
68. Francis AW, Dawson DL, Golijani-Moghaddam N. The development and validation of the Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT). *J Context Behav Sci*. 2016;5(3):134–45.
69. Rolffs JL, Rogge RD, Wilson KG. Disentangling Components of Flexibility via the Hexaflex Model: Development and Validation of the Multidimensional Psychological Flexibility Inventory (MPFI). *Assessment*. 2018;25(4):458–82.
70. Gould RL, Thompson BJ, Rawlinson C, Kumar P, White D, Serfaty MA, et al. A randomised controlled trial of acceptance and commitment therapy plus usual care compared to usual care alone for improving psychological health in people with motor neuron disease (COMMEND): study protocol. *BMC Neurol*. 2022;22(1):431.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

